Use of nf-kappa b inhibitors for the treatment of mastitis

• US 20060240011A1
• Filed: 08/12/2003
• Published: 10/26/2006
• Est. Priority Date: 08/14/2002
• Status: Abandoned Application

• Current Assignee: Janssen Pharmaceutica NV (Johnson & Johnson)
• Original Assignee: Université de Liège
• Inventors: Bureau, Fabrice, Boulanger, Delphine, Lekeux, Pierre
• Application Number:
  US10/523,836
• Publication Number:
  US 20060240011A1
• Time in Patent Office: Days
• US Class Current: 424/145.100
• CPC Class Codes: A61K 31/00 Medicinal preparations containing organic active ingredients
• CPC Class Codes: A61K 31/223 of alpha-aminoacids
• CPC Class Codes: A61K 31/277 having a ring, e.g. verapamil
• CPC Class Codes: A61K 31/325 Carbamic acids; Thiocarbamic acids; Anhydrides or salts thereof thiurams A61K31/145
• CPC Class Codes: A61K 31/352 condensed with carbocyclic rings, e.g. methantheline cannabinoids A61K31/658
• CPC Class Codes: A61K 31/415 1,2-Diazoles
• CPC Class Codes: A61K 31/4985 Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
• CPC Class Codes: A61K 31/69 Boron compounds
• CPC Class Codes: A61K 45/06 Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
• CPC Class Codes: A61P 15/00 Drugs for genital or sexual disorders for disorders of sex hormones A61P5/24; Contraceptives
• CPC Class Codes: A61P 15/14 for lactation disorders, e.g. galactorrhoea
• CPC Class Codes: A61P 31/04 Antibacterial agents
• CPC Class Codes: A61P 43/00 Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Abstract

The present invention relates to the use of NF-KB (NF-kappa B) inhibitors for the manufacture of a medicament for the treatment of mastitis.

Claims

1. (canceled)

4. (canceled)

8. A method for the treatment of mastitis comprising administering to a subject in need thereof an effective amount of a NF-κ

B inhibitor.

2. The method of claim 8 wherein mastitis is chronic mastitis.

3. The method of claim 8 wherein mastitis is acute mastitis.

5. The method of claim 8 wherein the NF-κ

B inhibitor is a specific NF-κ

B inhibitor.

6. The method of claim 8 wherein the NF-κ

B inhibitor is selected from 15d-PGJ2, tepoxalin, cycloepoxydon, (+)-cycloepoxydon, (−

)-cyclo-epoxydon, sodium diethyldithiocarbamate, gliotoxin, MG-132, BAY 11-7082, BAY 11-7085 or bortezomib.

7. The method of claim 8 wherein the NF-κ

B inhibitor is administered intramammary.

10. The method of claim 2, wherein the NF-κ

B inhibitor is selected from 15d-PGJ2, tepoxalin, cycloepoxydon, (+)-cycloepoxydon, (−

)-cyclo-epoxydon, sodium diethyldithiocarbamate, gliotoxin, MG-132, BAY 11-7082, BAY 11-7085 or bortezomib.

11. The method of claim 3, wherein the NF-κ

B inhibitor is selected from 15d-PGJ2, tepoxalin, cycloepoxydon, (+)-cycloepoxydon, (−

)-cyclo-epoxydon, sodium diethyldithiocarbamate, gliotoxin, MG-132, BAY 11-7082, BAY 11-7085 or bortezomib.

9. A method for the treatment of mastitis comprising administering to a subject in need thereof an effective amount of a NF-κ

B inhibitor in combination with an antibiotic.